CARDIOVASCULAR DRUGS AND THERAPY

Scope & Guideline

Championing breakthroughs in heart health solutions.

Introduction

Welcome to the CARDIOVASCULAR DRUGS AND THERAPY information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of CARDIOVASCULAR DRUGS AND THERAPY, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN0920-3206
PublisherSPRINGER
Support Open AccessNo
CountryNetherlands
TypeJournal
Convergefrom 1987 to 2024
AbbreviationCARDIOVASC DRUG THER / Cardiovasc. Drugs Ther.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressVAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS

Aims and Scopes

The journal "Cardiovascular Drugs and Therapy" focuses on the pharmacological aspects of cardiovascular diseases and therapies, emphasizing the efficacy, safety, and mechanisms of various cardiovascular drugs. It serves as a critical platform for disseminating research findings that explore drug interactions, treatment outcomes, and innovative therapeutic strategies in the field of cardiovascular medicine.
  1. Pharmacotherapy in Cardiovascular Diseases:
    The journal discusses various pharmacological treatments for cardiovascular diseases, including antiplatelet agents, anticoagulants, lipid-lowering drugs, and antihypertensives, analyzing their efficacy, safety, and clinical implications.
  2. Clinical Trials and Meta-analyses:
    It publishes results from clinical trials and meta-analyses that evaluate the effectiveness of new and existing cardiovascular therapies, providing evidence-based insights for clinicians and researchers.
  3. Mechanisms of Cardiovascular Drugs:
    Research on the underlying mechanisms of action of cardiovascular drugs is a focus area, exploring how these drugs interact at the molecular and cellular levels to influence cardiovascular health.
  4. Innovative Therapeutic Strategies:
    The journal highlights novel approaches to cardiovascular treatment, including the development of new drug formulations, combination therapies, and the use of genetic and biomarker information to tailor treatments.
  5. Real-World Evidence and Pharmacovigilance:
    It emphasizes the importance of real-world data and pharmacovigilance studies in understanding the long-term safety and effectiveness of cardiovascular therapies, informing clinical practice.
The journal "Cardiovascular Drugs and Therapy" has identified several emerging trends and themes that reflect the evolving landscape of cardiovascular research and therapy. These topics are gaining traction and are likely to shape future research directions.
  1. Precision Medicine in Cardiovascular Therapy:
    There is a growing focus on precision medicine approaches, including pharmacogenomics, that tailor cardiovascular treatments based on individual genetic and molecular profiles to enhance efficacy and safety.
  2. Role of SGLT2 Inhibitors:
    SGLT2 inhibitors have become a significant area of research, with numerous studies exploring their cardiovascular benefits beyond glycemic control, particularly in heart failure and renal protection.
  3. Anticoagulation Strategies in Atrial Fibrillation:
    Research into optimizing anticoagulation strategies for atrial fibrillation patients is trending, particularly regarding the comparative effectiveness of direct oral anticoagulants versus traditional therapies.
  4. Cardiovascular Impacts of Diabetes Medications:
    The intersection of diabetes management and cardiovascular health is increasingly prominent, with studies examining the cardiovascular effects of GLP-1 receptor agonists and other diabetes medications.
  5. Long-term Outcomes of Cardiovascular Interventions:
    There is an emerging emphasis on the long-term outcomes of various cardiovascular interventions, including surgical and catheter-based procedures, highlighting the importance of sustained patient follow-up.

Declining or Waning

While many areas continue to thrive, certain themes in the journal "Cardiovascular Drugs and Therapy" have shown a declining interest or frequency of publication. These waning scopes may reflect shifts in research priorities or advancements in the field that have rendered some topics less relevant.
  1. Traditional Antihypertensive Therapies:
    There appears to be a reduction in studies focusing solely on traditional antihypertensive medications, as newer classes of drugs and combination therapies gain prominence in clinical practice.
  2. Single-Agent Studies:
    Research focused exclusively on single-agent therapies is declining, with a noticeable shift towards combination therapies and multi-drug regimens that reflect contemporary clinical practice.
  3. Pharmacokinetics of Established Drugs:
    There is less emphasis on the pharmacokinetics of well-established cardiovascular drugs, as research increasingly prioritizes new therapeutic agents and innovative treatment strategies.
  4. Animal Model Studies:
    The prevalence of studies using traditional animal models to evaluate drug efficacy is decreasing, potentially due to a growing focus on human clinical trials and translational research.
  5. Generalized Risk Factor Studies:
    Research that broadly addresses cardiovascular risk factors without a direct link to specific therapeutic interventions is diminishing, as the emphasis shifts towards targeted therapeutic approaches.

Similar Journals

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Advancing cardiovascular health through innovative pharmacology.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0160-2446Frequency: 12 issues/year

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, published by LIPPINCOTT WILLIAMS & WILKINS, is a leading peer-reviewed journal dedicated to the exploration and advancement of pharmacological therapies related to cardiovascular diseases. With its ISSN 0160-2446 and E-ISSN 1533-4023, this esteemed journal has been at the forefront of cardiovascular research since its inception in 1979, continuously offering insights until 2024. It holds a commendable position in the 2023 category quartiles, classified as Q2 in both Cardiology and Cardiovascular Medicine, as well as Medicine (miscellaneous) and Pharmacology, showcasing its significance within these fields. The journal presents a unique platform for researchers, health professionals, and students to disseminate their findings, fostering an environment of knowledge growth and collaboration in cardiovascular pharmacology. Readers can expect to find high-quality articles that contribute to the body of knowledge in cardiovascular therapies, ensuring they remain informed of the latest advancements and clinical practices. Discover more about this influential publication and its commitment to enhancing cardiovascular health.

BASIC RESEARCH IN CARDIOLOGY

Shaping the future of cardiology with impactful studies.
Publisher: SPRINGER HEIDELBERGISSN: 0300-8428Frequency: 6 issues/year

BASIC RESEARCH IN CARDIOLOGY, published by SPRINGER HEIDELBERG, is an esteemed peer-reviewed journal dedicated to advancing the field of cardiology and cardiovascular medicine since 1973. With a strong emphasis on the latest breakthroughs in basic and translational research, this journal offers a platform for high-quality, impactful studies that contribute to our understanding of cardiac function and related physiological processes. Currently ranked in the Q1 category in Cardiology and Cardiovascular Medicine, as well as Physiology and Medical Physiology, BASIC RESEARCH IN CARDIOLOGY is recognized as a leading journal within these disciplines, boasting impressive Scopus ranks that place it in the top tiers of global research output. While it does not offer open access, its contributions are pivotal for researchers, clinicians, and students seeking to stay abreast of cutting-edge discoveries and methodologies in cardiovascular science. With its commitment to scholarly excellence, this journal plays a critical role in shaping the future of cardiac research and clinical practice.

EXPERT OPINION ON INVESTIGATIONAL DRUGS

Elevating Research through Expert Analysis
Publisher: TAYLOR & FRANCIS LTDISSN: 1354-3784Frequency: 12 issues/year

Expert Opinion on Investigational Drugs, published by Taylor & Francis Ltd, is a premier journal dedicated to the dissemination of high-quality, peer-reviewed research in the fields of pharmacology and medicine. As an integral part of the scientific community since its inception in 1994, this journal has established itself as a leading source of insightful analysis and expert commentary on emerging drug therapies, providing invaluable resources for researchers, clinicians, and healthcare professionals. With an impressive impact factor and ranking in the top quartile across multiple pharmacological categories, it remains a vital platform for discussing innovative drug developments and their clinical applications. Though it operates on a subscription basis, Expert Opinion on Investigational Drugs is crucial for anyone involved in pharmacological research and the drug development process, positioning itself at the forefront of medical advancements and offering critical insights into the rapid evolution of investigational therapies.

CIRCULATION JOURNAL

Exploring the Frontiers of Heart Health Research.
Publisher: JAPANESE CIRCULATION SOCISSN: 1346-9843Frequency: 12 issues/year

CIRCULATION JOURNAL, published by the Japanese Circulation Society, stands as a premier platform for cutting-edge research in the fields of Cardiology and Cardiovascular Medicine. With an impressive impact factor placing it in the Q1 quartile for both cardiology and general medicine, this journal is essential for researchers and practitioners seeking to stay at the forefront of cardiovascular science. The journal's accessible open access options ensure that groundbreaking studies are widely disseminated, reflecting its commitment to advancing medical knowledge and improving patient care. Since its inception in 1996, CIRCULATION JOURNAL has fostered a global dialogue on vital cardiovascular issues, making it a vital resource for academics, healthcare professionals, and students alike. With its base in Tokyo, Japan, the journal not only highlights regional advancements but also contributes significantly to the global medical community.

Current Vascular Pharmacology

Unveiling Breakthroughs in Vascular Therapeutics
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1570-1611Frequency: 6 issues/year

Current Vascular Pharmacology is a premier academic journal published by Bentham Science Publications Ltd, focusing on the intersection of pharmacology and cardiovascular medicine. With an impact factor that reflects its significance in the field, this journal ranks in the Q1 category for both Pharmacology and Cardiology, showcasing its dedication to high-quality research. Its Scopus ranks place it in the top percentile of its categories, highlighting its influence among scholars and practitioners alike. Issued since 2003 and continuing through 2024, Current Vascular Pharmacology aims to disseminate cutting-edge findings and foster knowledge exchange among researchers, professionals, and students engaged in cardiovascular pharmacology. Despite being a subscription-based journal, it remains a vital resource for those seeking the latest advancements in drug development and therapeutic interventions for vascular diseases. Located in the United Arab Emirates, the journal serves as an essential platform for global discourse on vascular health.

COR ET VASA

Advancing cardiovascular knowledge since 1961.
Publisher: CZECH SOC CARDIOLOGY & CZECH SOC CARDIOVASCULAR SURGERYISSN: 0010-8650Frequency: 6 issues/year

COR ET VASA is a prominent peer-reviewed journal in the field of cardiology and cardiovascular medicine, published by the Czech Society of Cardiology and Czech Society of Cardiovascular Surgery. Established in 1961, and continuing its legacy from 2006 to 2024, this journal serves as an essential platform for disseminating significant research findings, clinical studies, and innovative treatments in cardiovascular health. While currently positioned in the Q4 quartile, the journal aims to enhance its impact by fostering knowledge sharing among researchers, clinicians, and students alike. The journal, with its publication in Czech Republic, provides a unique perspective to the European cardiovascular community, allowing for invaluable insights and discourse. Researchers are encouraged to submit their manuscripts and contribute to the growing body of knowledge in this critical area, although it should be noted that COR ET VASA does not offer open access options at this time. As the field of cardiovascular medicine evolves, COR ET VASA remains committed to addressing the latest challenges and advancements, nurturing a rich dialogue within the community.

Journal of Cardiovascular Medicine

Pioneering Insights for a Healthier Heart
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1558-2027Frequency: 12 issues/year

Welcome to the Journal of Cardiovascular Medicine, a leading platform for the dissemination of high-quality research in the field of cardiology and cardiovascular medicine. Published by Lippincott Williams & Wilkins, this esteemed journal boasts an ISSN of 1558-2027 and an E-ISSN of 1558-2035, reflecting its commitment to accessible and innovative cardiovascular research. With a significant impact factor and ranked Q2 in both Cardiology and Cardiovascular Medicine as well as in Medicine (Miscellaneous) for 2023, the journal is recognized for its contributions to advancing knowledge and practice in this critical area of health. The journal disseminates original research, reviews, and clinical studies, aimed at clinicians, researchers, and healthcare professionals who are dedicated to improving cardiovascular health outcomes. With a continuous commitment to evolving research from 2006 to 2024, the journal is an essential resource for those looking to stay at the forefront of the latest discoveries and methodologies in cardiovascular medicine.

Expert Review of Cardiovascular Therapy

Enhancing Patient Care Through Rigorous Research
Publisher: TAYLOR & FRANCIS INCISSN: 1477-9072Frequency: 12 issues/year

Expert Review of Cardiovascular Therapy is a leading academic journal published by TAYLOR & FRANCIS INC, focusing on innovative and impactful research in the field of cardiovascular medicine. With an ISSN of 1477-9072 and an E-ISSN of 1744-8344, this journal serves as an essential resource for researchers, clinicians, and educators, offering a platform for the dissemination of critical advancements in cardiovascular therapy and internal medicine. Since its inception in 2003, the journal has maintained a reputable standing with a Q2 ranking in various categories including Cardiology and Cardiovascular Medicine, reflecting its influence and rigor in the field. The journal, which is based in the United Kingdom, does not currently offer Open Access options, ensuring that its content is accessible primarily to subscribers. With its commitment to high-quality, peer-reviewed articles, Expert Review of Cardiovascular Therapy is dedicated to bridging the gap between experimental research and clinical application, thereby enhancing patient care and therapeutic outcomes in cardiovascular health.

INVESTIGATIONAL NEW DRUGS

Driving Discoveries in Oncology and Pharmacology
Publisher: SPRINGERISSN: 0167-6997Frequency: 6 issues/year

INVESTIGATIONAL NEW DRUGS is a prestigious journal published by SPRINGER, dedicated to advancing research in the fields of pharmacology and oncology. With its origins dating back to 1983, the journal continues to play a critical role in disseminating groundbreaking studies and innovative methodologies related to drug development and therapeutic strategies. It holds an impressive impact factor among leading academic publications, ranking in the top quartiles (Q1 and Q2) of its respective categories, evidenced by Scopus rankings of #43/272 in Medical Pharmacology and #88/404 in Medical Oncology. While it offers traditional subscription-based access, it remains an essential resource for researchers, professionals, and students eager to stay abreast of significant advancements in drug research. Through rigorous peer review and comprehensive coverage, INVESTIGATIONAL NEW DRUGS aims to foster the development of effective new therapies and enhance our understanding of pharmacological interventions in oncology.

European Journal of Preventive Cardiology

Championing excellence in preventive cardiology research.
Publisher: OXFORD UNIV PRESSISSN: 2047-4873Frequency: 18 issues/year

The European Journal of Preventive Cardiology, published by Oxford University Press, is a leading international journal dedicated to the field of cardiology and cardiovascular medicine. With an impact factor that underscores its prestige—ranking in the top quartile (Q1) of both cardiology and epidemiology categories—the journal serves as a critical resource for researchers and practitioners seeking to advance their understanding of preventive strategies in cardiovascular health. Since its inception in 1999, it has provided a platform for high-quality research and reviews that address the epidemiology of cardiovascular diseases, risk factor management, and innovative prevention methodologies. Notably, it currently ranks #21 out of 387 in Medicine - Cardiology and #13 out of 148 in Medicine - Epidemiology according to Scopus, highlighting its influential position in these essential biomedical fields. The journal also provides open access options, allowing both readers and authors the opportunity to engage with groundbreaking research and enhance the dissemination of knowledge. With a commitment to excellence, the European Journal of Preventive Cardiology is an invaluable asset for those dedicated to the prevention of cardiovascular diseases.